Study details
Enrolling now
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
InSightec
NCT IDNCT03671889ClinicalTrials.gov data as of Apr 2026
Target enrollment
150
Study length
about 7.3 years
Ages
50–85
Locations
10 sites in FL, NY, OH +2
What this study is about
This trial is testing a device to disrupt the blood-brain barrier in people with probable Alzheimer's disease. The goal is to evaluate if this device is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Use Blood Brain Barrier (BBB) Disruption
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Device and procedure related adverse events
Body systems
Neurology